Altre lingue Genexine, Inc.

Azioni

A095700

KR7095700001

Prezzo di chiusura Korea S.E. Altri mercati azionari 00:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
7.280 ^KRW	-0,95%		+3,41%	-26,46%

2023	Genexine, Inc. riporta i risultati degli utili per il terzo trimestre e i nove mesi conclusi il 30 settembre 2023	CI
2023	Genexine, Inc. e PT Kalbe Genexine Biologics ricevono la prima approvazione del mercato per la nuova eritropoietina a lunga durata d'azione, Efepoetin Alfa, dall'Autorità indonesiana per gli alimenti e i farmaci (BPOM).	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Genexine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Genexine, Inc. and PT Kalbe Genexine Biologics Receives the First Market Approval for Novel Long-Acting Erythropoietin, Efepoetin Alfa, from the Indonesian Food and Drug Authority	23/10/23
Sector Update: Health Care Stocks Edge Higher Premarket Thursday	31/08/23
Sector Update: Health Care	31/08/23
Salesforce Earnings, Inflation Outlook Bolster Exchange-Traded Funds, Equity Futures Premarket Thursday	31/08/23
I-Mab's Phase 3 Trial of Growth Hormone Deficiency Drug Meets Primary Endpoint, Joint Venture Partner Says	31/08/23
Genexine Announces Positive Topline Results from the Multi-Center, Randomized, Open-Label, Active-Controlled Pivotal Phase 3 Study	31/08/23
Henlius Biotech Grants Hansizhuang License to Kalbe Genexine Biologics	28/08/23
Genexine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23
Genexine abstract on GX-188E and GX-I7 triple combination therapy in HNSCC is released at 2023 ASCO Annual Meeting	29/05/23
Genexine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
Genexine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	20/03/23
Genexine Receives Fast Track Designation from Korean Health Authority (MFDS) for its promising DNA vaccine for advanced cervical cancer	23/01/23
Genexine Receives Fast Track Designation from Korean Health Authority for Its Promising DNA Vaccine for Advanced Cervical Cancer	20/01/23
Genexine, Inc. to Present Final Phase 2 Clinical Data on Its Cervical Cancer Program Showing a 35.0% Overall Response Rate and Provide a Corporate Overview During JP Morgan Conference	09/01/23
Genexine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22
Genexine to Raise $70 Million via Share Issuance	26/09/22
Genexine’s Announces that DNA Vaccine Shows Significant Potential to Extend Survival in Late-Stage Cervical Cancer	08/09/22
Genexine selected for Late-Breaking Oral Presentation of Phase 2 Study of GX-188E in Combination with KEYTRUDA (pembrolizumab) in Cervical Cancer at European Society for Medical Oncology (ESMO) Congr	25/08/22
Genexine to Present Phase 2 Study of GX-188E in Combination with KEYTRUDA® (pembrolizumab) in Cervical Cancer at European Society for Medical Oncology Congress 2022	25/08/22

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Genexine, Inc.

Azioni

A095700

KR7095700001

Altre lingue

Filtri